Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

医学 放射治疗 叶黄素 奥沙利铂 氟尿嘧啶 随机对照试验 中期分析 新辅助治疗 外科 内科学 化疗 癌症 结直肠癌 乳腺癌
作者
Matthew H. G. Katz,Qian Shi,Jeff Meyers,Joseph M. Herman,Michael D. Chuong,Brian M. Wolpin,Syed A. Ahmad,Robert Marsh,Lawrence H. Schwartz,Spencer C. Behr,Wendy L. Frankel,Eric A. Collisson,James L. Leenstra,Terence M. Williams,Gina M. Vaccaro,Alan P. Venook,Jeffrey A. Meyerhardt,Eileen M. O’Reilly
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:8 (9): 1263-1263 被引量:148
标识
DOI:10.1001/jamaoncol.2022.2319
摘要

Importance National guidelines endorse treatment with neoadjuvant therapy for borderline resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains unclear. Objective To compare treatment with neoadjuvant modified FOLFIRINOX (mFOLFIRINOX) with or without hypofractionated radiation therapy with historical data and establish standards for therapy in borderline resectable PDAC. Design, Setting, and Participants This prospective, multicenter, randomized phase 2 clinical trial conducted from February 2017 to January 2019 among member institutions of National Clinical Trials Network cooperative groups used standardized quality control measures and included 126 patients, of whom 70 (55.6%) were registered to arm 1 (systemic therapy; 54 randomized, 16 following closure of arm 2 at interim analysis) and 56 (44.4%) to arm 2 (systemic therapy and sequential hypofractionated radiotherapy; all randomized before closure). Data were analyzed by the Alliance Statistics and Data Management Center during September 2021. Interventions Arm 1: 8 treatment cycles of mFOLFIRINOX (oxaliplatin, 85 mg/m 2 ; irinotecan, 180 mg/m 2 ; leucovorin, 400 mg/m 2 ; and infusional fluorouracil, 2400 mg/m 2 ) over 46 hours, administered every 2 weeks. Arm 2: 7 treatment cycles of mFOLFIRINOX followed by stereotactic body radiotherapy (33-40 Gy in 5 fractions) or hypofractionated image-guided radiotherapy (25 Gy in 5 fractions). Patients without disease progression underwent pancreatectomy, which was followed by 4 cycles of treatment with postoperative FOLFOX6 (oxaliplatin, 85 mg/m 2 ; leucovorin, 400 mg/m 2 ; bolus fluorouracil, 400 mg/m 2 ; and infusional fluorouracil, 2400 mg/m 2 over 46 hours). Main Outcomes and Measures Each treatment arm’s 18-month overall survival (OS) rate was compared with a historical control rate of 50%. A planned interim analysis mandated closure of either arm for which 11 or fewer of the first 30 accrued patients underwent margin-negative (R0) resection. Results Of 126 patients, 62 (49%) were women, and the median (range) age was 64 (37-83) years. Among the first 30 evaluable patients enrolled to each arm, 17 patients in arm 1 (57%) and 10 patients in arm 2 (33%) had undergone R0 resection, leading to closure of arm 2 but continuation to full enrollment in arm 1. The 18-month OS rate of evaluable patients was 66.7% (95% CI, 56.1%-79.4%) in arm 1 and 47.3% (95% CI 35.8%-62.5%) in arm 2. The median OS of evaluable patients in arm 1 and arm 2 was 29.8 (95% CI, 21.1-36.6) months and 17.1 (95% CI, 12.8-24.4) months, respectively. Conclusions and Relevance This randomized clinical trial found that treatment with neoadjuvant mFOLFIRINOX alone was associated with favorable OS in patients with borderline resectable PDAC compared with mFOLFIRINOX treatment plus hypofractionated radiotherapy; thus, mFOLFIRINOX represents a reference regimen in this setting. Trial Registration ClinicalTrials.gov Identifier: NCT02839343
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
内向的浩宇完成签到,获得积分10
刚刚
Bluebulu发布了新的文献求助10
刚刚
大龙哥886发布了新的文献求助10
刚刚
1秒前
XUEBJ完成签到 ,获得积分10
1秒前
1秒前
1秒前
1秒前
天天快乐应助LiDaYang采纳,获得30
2秒前
烂瞓发布了新的文献求助10
3秒前
刘茂甫完成签到,获得积分10
3秒前
NexusExplorer应助wwz采纳,获得10
3秒前
neuarcher应助勤奋草莓采纳,获得10
4秒前
ch3oh发布了新的文献求助10
5秒前
MM11111完成签到,获得积分10
5秒前
充电宝应助黄花菜采纳,获得10
6秒前
健忘天与发布了新的文献求助10
6秒前
Heart发布了新的文献求助10
7秒前
7秒前
7秒前
升升升呀应助科研通管家采纳,获得10
8秒前
星辰大海应助科研通管家采纳,获得10
8秒前
NexusExplorer应助科研通管家采纳,获得10
8秒前
烟花应助科研通管家采纳,获得20
8秒前
华仔应助科研通管家采纳,获得10
8秒前
科研通AI2S应助科研通管家采纳,获得10
8秒前
英俊的铭应助科研通管家采纳,获得10
8秒前
NexusExplorer应助科研通管家采纳,获得10
8秒前
8秒前
我是老大应助科研通管家采纳,获得10
8秒前
华仔应助科研通管家采纳,获得10
8秒前
Ava应助科研通管家采纳,获得10
9秒前
9秒前
9秒前
wanci应助科研通管家采纳,获得30
9秒前
9秒前
深情安青应助科研通管家采纳,获得10
9秒前
9秒前
一路硕博应助科研通管家采纳,获得10
9秒前
Akim应助科研通管家采纳,获得10
9秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3083106
求助须知:如何正确求助?哪些是违规求助? 2736348
关于积分的说明 7540888
捐赠科研通 2385732
什么是DOI,文献DOI怎么找? 1265111
科研通“疑难数据库(出版商)”最低求助积分说明 612929
版权声明 597702